ALKS Stock Recent News

GE Aerospace has formed a flat base, one of several stocks with strong relative strength near buy points and with relatively low volatility. The post GE Aerospace Leads Five Stocks Near Buy Points With This Bullish Trait appeared first on Investor's Business Daily.

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45th Annual Health Care Conference Date/Time: Wednesday, March 5, 2025 at 9:50 a.m.

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year.

Alkermes plc (NASDAQ:ALKS ) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - Chairman and Chief Executive Officer Blair Jackson - Executive Vice President and Chief Operating Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Umer Raffat - Evercore ISI Jessica Fye - JPMorgan Chris Shibutani - Goldman Sachs Marc Goodman - Leerink Partners Uy Ear - Mizuho Securities Troy Langford - TD Cowen Douglas Tsao - H.C. Wainwright Joel Beatty - Baird Operator Greetings, and welcome to the Alkermes Fourth Quarter 2024 Financial Results Conference Call.

Alkermes (ALKS 2.50%), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported robust financial results, beating analyst estimates with a non-GAAP EPS of $1.04 against an expected $0.76.

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes (ALKS) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.48 per share a year ago.

—    Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — —    GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 — —    ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 — DUBLIN , Feb. 12, 2025  /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2024 and provided financial expectations for 2025. "2024 marked the completion of a multi-year effort to transition the business into a highly profitable, pure-play neuroscience company.